Missense mutations of JAK and STAT genes are frequently found in T-PLL. However, sequencing analyses of the JAK/STAT pathway have been performed in small cohorts, due to the limited number of patient samples. Here we conducted a meta-analysis that re-evaluated the genomic landscape of the JAK/STAT pathway and its regulators in 275 T-PLL cases. Interestingly, next to gain of function mutations in JAK and STAT genes, a significant proportion of genes encoding for potential negative regulators of STAT5B showed genomic losses. Overall, considering such losses of negative regulators and the GOF mutations in JAK and STAT genes, we found that a total of 89.8% of T-PLL revealed a genomic aberration potentially explaining enhanced STAT5B activity.
Read the paper:Postet on November 21, 2019
On October 30th, Sebastian Oberbeck successfully defended his PhD. The title of his thesis: “The T-cell receptor and it’s signaling in T-cell Prolymphocytic Leukemia”. Congratulations!Postet on October 30, 2019
On October 23th, Sabine Pützer successfully defended her PhD. Congratulations!Postet on October 23, 2019
The Consortium for TCR-mediated Regulation and Oncogenesis in Lymphomas of T cells (CONTROL-T) invites you to take part in the “International Symposium on T cells and T-cell lymphomas” on September 20-21, 2019, in Essen (Germany). This summit will bring together leading experts from the fields of pathology, genomics, imaging, modeling, cell signaling, cellular immunology, medical oncology, and experimental cell therapy dealing with normal T-cell biology and T-cell lymphomas.
For further information please see: CONTROL-T CONFERENCE 2019
or:Postet on August 20, 2019